Core Viewpoint - Questerre Energy Corporation is responding to a recent ruling by the Court of Appeal of Quebec regarding Bill 21, which affects petroleum exploration and production in the region, and plans to appeal to the Supreme Court of Canada [2][3]. Legal Context - The Court of Appeal recognized serious constitutional issues with Bill 21 and reinstated certain provisions, allowing the Quebec government to potentially enforce abandonment and reclamation of existing wells [2]. - The ruling overturned a previous decision by the Quebec Superior Court that had suspended key provisions of Bill 21 [2][3]. - The Court of Appeal found that the original Justice erred in the balance of convenience test and did not adequately consider the public interest in suspending Bill 21 [3]. Company Overview - Questerre is positioned as an energy technology and innovation company, focusing on responsibly producing and utilizing energy through clean technologies [4]. - The company emphasizes the importance of balancing economics, environment, and society for the future success of the oil and gas industry [5].

Company Overview - Sernova Biotherapeutics is a clinical-stage company focused on developing regenerative medicine therapeutics, specifically its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D) [3] - The company collaborates with Evotec to create Bio-hybrid Organs that integrate human donor cells or stem-cell derived islet-like clusters with its Cell Pouch [3] Recent Developments - Mr. Ross Haghighat resigned as Chair of Sernova Biotherapeutics on May 24, 2025, and his resignation was accepted by the Board of Directors [2] - The Board expressed gratitude for Mr. Haghighat's service and wished him well in his future endeavors [2] Product Focus - The Bio-hybrid Organ developed by Sernova consists of non-biomaterials, such as the Cell Pouch, combined with living tissues to restore or enhance the function of compromised organs [3] - The initial focus of Sernova's innovative approach is on treating chronic diseases, particularly T1D and thyroid disorders [3]

Core Viewpoint - Canyon Resources Limited has secured a medium-term syndicated credit facility of approximately US$140 million from AFG Bank Cameroon to fund the development of its Minim Martap Bauxite Project in Cameroon, alongside additional funding from its major shareholder, Eagle Eye Asset Holdings [1][2][7]. Group 1: Credit Facility Details - The credit facility amounts to XAF 82,000,000,000 (approximately US$140 million) and is structured as a syndicated medium-term loan [11]. - The interest rate for the facility is fixed at 8.00% per annum plus VAT, with a repayment term of 8 years from the first drawdown [11]. - The drawdown is anticipated to occur in Q3 2025, with conditions including the opening of project accounts and guarantees from Canyon Resources Limited [3][11]. Group 2: Project Development - The funds from the credit facility will be utilized for acquiring locomotives, wagons, and developing rail and port infrastructure for the Minim Martap Bauxite Project [2]. - Since obtaining the Mining License in September 2024, Canyon has made significant progress, including securing key land for port and rail facilities, and is now focused on making a Final Investment Decision [5][6]. - The company aims to commence its first shipment of bauxite from Minim Martap in the first half of 2026 [5]. Group 3: Stakeholder Support - Eagle Eye Asset Holdings intends to exercise 350 million options for AU$24.5 million to further support the funding of Stage One operations at Minim Martap [2][7]. - AFG Bank Cameroon is recognized as a strong partner for Canyon, demonstrating expertise in structured financing and commitment to providing tailored financial solutions [4][7].

Core Viewpoint - Glass Lewis, an independent proxy advisory firm, has recommended that stockholders vote "FOR" the compensation proposal for Radware's president and CEO at the upcoming Extraordinary General Meeting [1][2] Group 1: Compensation Proposal - The annual bonus and long-term equity incentives for Radware's president and CEO are found to be appropriately aligned with performance and market practices [2] - The compensation structure has been modified to enhance the alignment of pay and performance, benefiting shareholders [3] Group 2: Meeting Details - The Extraordinary General Meeting will take place on May 29, 2025, at 8:00 a.m. (EDT) at Radware's offices in Mahwah, N.J. [3] - The record date for the Meeting is April 25, 2025 [3] Group 3: Company Overview - Radware is a global leader in application security and delivery solutions for multi-cloud environments, utilizing AI-driven algorithms for real-time protection against sophisticated cyber threats [6]

– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted) and a 19.0 mmHg reduction at Week 12 (-11.7mm placebo adjusted) – – Lorundrostat demonstrated a favorable s ...

Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's Annual General Meeting held on 29 April 2025 to grant the Company's Board of Directors an authorisation to issue new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The Company's Board of Directors has today resolved to issue 227,096 new shares in the Company to Inven2 against set-off of such amount of EUR 500,000. After the ...

Core Viewpoint - NextGen Digital Platforms Inc. has successfully completed the third and final tranche of its non-brokered private placement, raising a total of approximately $2.83 million through the issuance of special warrants and common shares [1][3]. Group 1: Offering Details - The third tranche involved the issuance of 2,468,032 special warrants at a price of $0.30 each, generating gross proceeds of $740,409.74 [1]. - In total, the company issued 8,979,498 special warrants and 440,000 common shares during the entire offering, resulting in total gross proceeds of $2,825,849.84 [3]. - The company paid finder's fees totaling $54,712.01 in cash and issued 162,533 Finder's Warrants as part of the offering [3]. Group 2: Special Warrants Conversion - Each special warrant will automatically convert into one common share without additional consideration, either three business days after filing a prospectus supplement or four months and one day after the offering's closing [4]. - The company aims to file the prospectus supplement within 60 days of the offering's closing, although there is no guarantee this will occur before the statutory hold period expires [5]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for corporate development, marketing, and general working capital [6]. Group 4: Marketing Agreement - The company has entered into a marketing agreement with Alpha Collective Inc. for digital marketing services, with a cash fee of $45,000 for a three-month term starting May 21, 2025 [7].

Core Viewpoint - BioSig Technologies, Inc. has signed a definitive share exchange agreement with Streamex Exchange Corporation, marking a significant milestone in the business combination aimed at enhancing the tokenization of real-world assets, particularly in the commodities sector [1][2]. Company Overview - BioSig Technologies is a medical technology company focused on innovative solutions, while Streamex specializes in the tokenization of real-world assets, particularly commodities [1][7]. - The combined entity will be led by Henry McPhie, Co-Founder and CEO of Streamex, with Anthony Amato transitioning to a board role [5]. Transaction Highlights - The share exchange will result in Streamex becoming a wholly owned subsidiary of BioSig, with existing Streamex shareholders entitled to receive 75% of the fully diluted BioSig common stock post-transaction [5][12]. - The transaction is expected to unlock new value in the US$142.85 trillion global commodity market by bringing commodities on-chain through secure tokenization solutions [5][13]. Strategic Additions - Notable strategic advisors have joined the combined company, including Frank Giustra, Mathew August, and Mitchell Williams, bringing extensive experience in commodities and capital markets [6]. Market Positioning - Streamex aims to revolutionize commodity finance by bridging traditional finance with the digital economy, enhancing liquidity, accessibility, and efficiency through innovative financial technologies and blockchain [8].

Core Points - Advent Technologies Holdings, Inc. has received a notification from Nasdaq regarding non-compliance with listing requirements due to late filings of its Quarterly Report on Form 10-Q and Annual Report on Form 10-K [1][2] - The company has until June 16, 2025, to submit a compliance plan to Nasdaq, which, if accepted, may allow an extension until October 13, 2025, to regain compliance [2][3] - Advent Technologies specializes in developing and manufacturing fuel cell systems and holds over 150 patents related to fuel cell technology [4] Company Overview - Advent Technologies Holdings, Inc. is based in Livermore, California, with additional offices in Athens and Patras, Greece [4] - The company focuses on renewable energy, particularly in fuel cell technology, suitable for various sectors including automotive, aviation, defense, oil and gas, marine, and power generation [4] - The company possesses intellectual property for next-generation HT-PEM fuel cells that operate under high temperatures and extreme conditions [4]

Core Viewpoint - IMUNON, Inc. has announced a private placement of common stock and short-term warrants, aiming to raise approximately $3.25 million, with potential additional proceeds of up to $6.5 million from the exercise of warrants [1][3]. Group 1: Financial Details - The company will issue 7,222,223 shares of common stock at a price of $0.45 per share, along with short-term warrants to purchase up to 14,444,446 additional shares [1][3]. - The offering is expected to close around May 27, 2025, pending customary closing conditions [1]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 2: Regulatory and Offering Structure - The securities are offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered under the Act [4]. - The offering is limited to accredited investors, and the company has agreed to file registration statements with the SEC for resale of the shares [4]. Group 3: Company Overview - IMUNON is a clinical-stage biotechnology company focused on DNA-mediated immunotherapy, with a lead program targeting advanced ovarian cancer [6][7]. - The company is developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [6]. - IMUNON's first modality, TheraPlas, is aimed at gene-based delivery of therapeutic proteins, while the second modality, PlaCCine, focuses on gene delivery of viral antigens [6].